A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis

Journal of Rheumatology

Volumn 26, Issue 5, 1999, Pages 1148-1157

  Homik, Joanne E ^a   Cranney, Ann ^b   Shea, Beverly ^b   Tugwell, Peter ^b   Wells, George ^b   Adachi, Jonathan D ^c   Suarez Almazor, Maria E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Bisphosphonates; Corticosteroids; Metaanalysis; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; ETIDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MINERALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FRACTURE; HUMAN; META ANALYSIS; OSTEOPOROSIS; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; AGED; BONE DENSITY; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS;

EID: 0032930651     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG. Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 1989;48:535-8.
2. LeBoff MS, Wade JP, Mackowiak S, El-Haji Fuleihan G, Zangari M, Liang MH. Low does prednisone dose not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis. J Rheumatol 1991;18:339-44.
3. Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Int 1990;5:164-8.
4. Nordborg E, Hansson T, Jonson R, Szucs J, Bengtsson BA. Bone mineral content of the third lumbar vertebra during 18 months of prednisolone treatment for giant cell arteritis. Clin Rheumatol 1993;12:455-60.
5. Als OS, Gotfredsen A, Christiansen C. The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state. Arthritis Rheum 1985;28:369-75.
6. Pons F, Peris P, Guanabens N, et al. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in premenopausal women. Br J Rheumatol 1995;34:742-6.
7. Jennings BH, Andersson KE, Johansson SA. The assessment of the systemic effects of inhaled glucorticosteroids. The effects of inhaled budesonide vs oral prednisolone on calcium metabolism. Eur J Clin Pharmacol 1991;41:11-6.
8. Gennari C. Differential effect of glucocorticoids on calcium absorption and bone mass. Br J Rheumatol 1993;32 Suppl 2:11-4.
9. Montecucco C, Caporali R, Caprotti P, Caprotti M, Notario A. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol 1992;19:1895-900.
10. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Min Res 1989;4:137-41.
11. Meeran K, Hattersley A, Burrin J, Shiner R, Ibbertson K. Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am J Respir Crit Care Med 1995;151:333-6.
12. Prummel MF, Wiersinga WM. Lips P, Sanders GT, Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991;72:382-6.
13. Peat ID, Healy S, Reid DM, Ralston SH. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis 1995;54:66-8.
14. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
15. Adachi J, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994;21:1922-6.
16. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
17. Worth H, Stammen D, Keck E. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate. Am J Respir Crit Care Med 1994;150:394-7.
18. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
19. Skingle SJ, Crisp AJ. Increased bone density in patients on steroids with etidronate. Lancet 1994;344:543-4.
20. Gallacher SJ, Fenner JA, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992;47;932-6.
21. Van Cleemput J, Daenen W, Geusens P, Dequeker P, Van De Werf F, VanHaecke J. Prevention of bone loss in cardiac transplant recipients. A comparison of bisphosphonates and vitamin D. Transplantation 1996;61:1495-9.
22. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet 1988;1:143-6.
23. Reid IR, Heap SW, King AR, Ibbertson HK. Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis [letter]. Lancet 1988;2:1144.
24. Sebaldt RJ, Adachi JD, Bensen WG, et al. Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: two years of follow-up. Scand J Rheumatol 1996;103 Suppl:91-3.
25. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
26. Pitt P, Li F, Bloom B, et al. A double-blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term corticosteroid treatment [abstract]. Bone 1997;20 Suppl 4:100S.
27. Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MID. The prevention of corticosteroid induced osteoporosis with intermittent cyclical etidronate [abstract]. Bone 1997;20 Suppl 4:103S.
28. Geusens P, Vanhoof J, Stalmans R, et al. Cyclic etidronate increases bone density in the spine and hip in postmenopausal women on chronic corticosteroid treatment. A double-blind controlled study [abstract]. Bone 1997;20 Suppl 4:9S.
29. Roux C, Oriente P, Laan R, et al. Etidronate in the prevention of corticosteroid induced bone loss: a randomized placebo-controlled prospective study. J Bone Min Res 1997;12 Suppl 1:S509.
30. Lane N, Genant H, Engleman E. Effect of intermittent cyclic etidronate (ICT) therapy for glucocorticoid-induced osteoporosis in rheumatoid arthritis: interim analysis [abstract]. Arthritis Rheum 1993; Suppl 36:S51.
31. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclic etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-63.
32. Eastell R, Devogelaer JP, Peel NFA, et al. A double-blind placebo-controlled study to determine the effects of risedonate on bone loss in glucocorticoid-treated rheumatoid arthritis patients [abstract]. J Bone Miner Res 1996;11:1812.
33. Krieg MA, Thiébaud D, Gillard-berguer D, Goy JJ, Burckhardt P. Intermittent intravenous pamidronate prevents the dramatic bone loss after heart transplantation [abstract]. J Bone Miner Res 1996;11:S345.
34. Wolfhagen F, van Buuren H, den Ouden J, et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. J Hepatol 1997;26:325-30.
35. Saag K, Emkey R, Gruber B, et al. Alendronate for the management of glucocorticoid-induced osteoporosis: results of the multicenter US study [abstract]. Arthritis Rheum 1997;40:Suppl:S136.
36. Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer J-P. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 1997;61:266-71.
37. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997;61:382-5.
38. Mulrow CD, Oxman AD, editors. Cochrane Collaboration Handbook. Updated September 1997. In: The Cochrane Library [database on disc and CD-ROM]. Oxford: The Cochrane Collaboration. Updated software; 1994, Issue 4.
39. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
40. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
41. Rickers H, Deding A, Christiansen C, Rodbro P, Mineral loss in cortical and trabecular bone during high-dose prednisone treatment. Calcif Tissue Int 1984;36:269-73.
42. Hedges L, Olkin I. Random effect models for effect sizes. In: Hedges L, Olkin I, editors. Statistical methods for meta-analysis. Orlando: Academic Press;1985:191-203.
43. Sackett D, Haynes R, Guyatt G, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. The clinical examination. 2nd ed. Boston: Little, Brown Company;1991:19-49.
44. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
45. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
46. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
47. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
48. Thiebaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996;26:549-55.
49. Sambrook PN, Kelly PJ, Keogh AM, et al. Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant 1994;13:116-20.
50. McDonald JA, Dunstan CR, Dilworth P, et al. Bone loss after liver transplantation. Hepatology 1991;14:613-9.
51. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991;325:544-50.
52. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988;123:2571-7.
53. Lufkin EG, Wahner HW, Bergstralh EJ. Reversibility of steroid-induced osteoporosis. Am J Med 1988;85:887-8.
54. Laan RF, van Riel P, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993;119:963-8.
55. Rizzato G, Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J 1993;6:116-9.